NCT07837973 Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
| NCT ID | NCT07837973 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Alveus Therapeutics, Inc. |
| Condition | Overweight , Obesity |
| Study Type | INTERVENTIONAL |
| Enrollment | 220 participants |
| Start Date | 2026-08-10 |
| Primary Completion | 2027-08-24 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 220 participants in total. It began in 2026-08-10 with a primary completion date of 2027-08-24.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A study of ALV-100 to assess efficacy, safety and tolerability among participants with overweight or obesity who have previously achieved a body weight reduction of ≥10% while treated with incretin-based therapies.
Eligibility Criteria
Key inclusion criteria 1. Adult male and female participants, aged ≥18 to ≤75 2. BMI ≥23 kg/m2 at screening. 3. Has been treated with incretin-based therapy for weight management at a stable dose for at least 3 continuous months prior to screening. 4. Tolerating incretin-based therapy at the discretion of the investigator 5. WL of at least 10% while on incretin-based therapy and with stable BW for at least 3 months prior to screening. 6. Willing to maintain their current general diet and physical activity regimen throughout the study. Key exclusion criteria 1. Lifetime history of Type 1 or Type 2 diabetes 2. Prior obesity treatment with surgery or a weight loss device. 3. Obesity caused by known endocrinologic disorders or by known congenital or acquired hypothalamic disease or monogenetic or syndromic forms of obesity. 4. Current or history of (within 3 months prior to screening) treatment with medications that may cause significant weight gain. 5. Family or personal history of MTC or MEN 2 6. Presence or history of malignant neoplasms within the past 5 years prior to screening
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07837973 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Overweight , Obesity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07837973 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07837973 currently recruiting?
Yes, NCT07837973 is actively recruiting participants. Contact the research team at clinicaltrials@alveustx.com for enrollment information.
Where is the NCT07837973 trial being conducted?
This trial is being conducted at Birmingham, United States, Sun City, United States, Tempe, United States, Oceanside, United States and 11 additional locations.
Who is sponsoring the NCT07837973 clinical trial?
NCT07837973 is sponsored by Alveus Therapeutics, Inc.. The trial plans to enroll 220 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.